Septerna is a clinical-stage biotechnology company utilizing its proprietary Native Complex Platform™ to discover and develop oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs). The company focuses on addressing significant unmet medical needs in endocrinology, immunology, and metabolic diseases by unlocking previously difficult-to-drug GPCRs.
Funding
$150M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
G protein-coupled receptors (GPCRs) are critical drug targets, but many remain difficult to target with traditional small molecule drugs. This limitation hinders the development of new treatments for a wide range of diseases.
Solution
Septerna is a biotechnology company that leverages its Native Complex Platform™ to discover and develop oral small molecule drug candidates specifically targeting difficult-to-drug GPCRs. The platform enables the identification of novel binding pockets and allosteric modulators, expanding the druggable GPCR space. Septerna's approach aims to create new medicines for patients with unmet needs across endocrinology, immunology, inflammation, and metabolic diseases. The company is advancing a pipeline of wholly-owned programs focused on these therapeutic areas.
Target Audience
The primary target audience includes patients with endocrine, immune, inflammatory, and metabolic diseases, as well as pharmaceutical companies seeking novel GPCR-targeted therapeutics.
Features
- Native Complex Platform™: An industrial-scale platform for GPCR drug discovery.
- Focus on oral small molecule drug candidates.
- Pipeline of programs in endocrinology, immunology and inflammation, and metabolic diseases.
- Targets previously difficult-to-drug GPCRs.